Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brinzolamide, quantity: 10 mg/ml - eye drops - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; tyloxapol; mannitol; carbomer 974p; hydrochloric acid; sodium hydroxide; purified water - azopt 1.0% eye drops are indicated to decrease intraocular pressure in : ocular hypertension; open-angle glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tobramycin, quantity: 3 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; boric acid; benzalkonium chloride; sodium hydroxide; tyloxapol; hydrochloric acid; sodium sulfate; purified water - tobrex(tobramycin) eye drops are topical antibiotics indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobrex.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tobramycin, quantity: 3 mg/g - eye ointment - excipient ingredients: liquid paraffin; white soft paraffin; chlorobutanol hemihydrate - indications as at 02 may 1984 : tobrex is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobrex.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops - excipient ingredients: sodium hydroxide; hydrochloric acid; dibasic sodium phosphate; benzalkonium chloride; citric acid monohydrate; water for injections; sodium chloride - bimtop is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops - excipient ingredients: sodium hydroxide; benzalkonium chloride; citric acid monohydrate; hydrochloric acid; dibasic sodium phosphate heptahydrate; purified water; sodium chloride - bimatoprost eye drops are indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml; timolol maleate, quantity: 6.8 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; purified water; hydrochloric acid - combigan eye drops are indicated for the reduction of elevated intraocular pressure for treatment of open angle glaucoma and/or ocular hypertension, in patients not adequately responding to monotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: hydrochloric acid; benzalkonium chloride; sodium hydroxide; purified water; citric acid monohydrate; dibasic sodium phosphate heptahydrate; sodium chloride - for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - latanoprost, quantity: 0.05 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; benzalkonium chloride; water for injections; monobasic sodium phosphate monohydrate - reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml (equivalent: betaxolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: purified water; disodium edetate; sodium chloride; hydrochloric acid; benzalkonium chloride; sodium hydroxide - indications as at 23 march 1999: betoquin eye drops 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoquin eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.